Capital Com MENA Securities Trading LLC is regulated by the Capital Market Authority.
Open platformOpen platform

Alphamab Oncology's Anbenitamab Regimen Cuts Progression or Death Risk 54% in Phase III Breast Cancer Trial

By Public Technologies
  • Alphamab Oncology presented results from two Phase III trials of anbenitamab (KN026) at the 2026 European Society for Medical Oncology Congress.
  • First-line anbenitamab with HB1801 delayed progression versus standard treatment in HER2-positive advanced breast cancer; China granted the application priority review.
  • In previously treated HER2-positive gastric or gastroesophageal junction cancer, anbenitamab with chemotherapy prolonged survival versus chemotherapy alone.
  • China cleared the gastric cancer regimen for marketing in May 2026 for patients previously treated with a trastuzumab-containing regimen.
  • Severe adverse events were more frequent with anbenitamab regimens in both trials, though the breast cancer study identified no new safety signals.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Alphamab Oncology published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20261026-12382704), on October 26, 2026, and is solely responsible for the information contained therein.

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.